
Siemens Healthineers AG
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Siemens Healthineers AG, along with its affiliated companies, offers a global portfolio of diagnostic and therapeutic solutions, which it designs, produces, and markets to healthcare organizations wor...
Latest News
1 month ago · businesswire.com
Sun Nuclear Announces Validated Adaptive QA Solution in Support of New Radiotherapy System, Accela, by Siemens HealthineersMELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, today announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technical experts and clinical partners for interoperability with the company's new radiotherapy system, Accela. Unveiled at the annual ASTRO conference, Accela is the first software-driven delivery system engineered for NeoArc (Dynamic Modulated Arc Therapy, DMAT), a new treatment technique that accelerates how radia.
2 months ago · seekingalpha.com
Siemens Healthineers: Successful Investment, Updating For H2 2026Siemens Healthineers remains a high-conviction BUY with a reiterated €48/share price target, reflecting strong Imaging and Precision Therapy segments. I exclude Chinese recovery from my base case; growth is now driven by ex-China Imaging and Varian, with diagnostics seen as structurally impaired. 3Q26 results confirmed robust order momentum (1.3x book-to-bill), and margin strength (19.1%), and EPS guidance raised to €2.45, though tariff refunds contributed.
3 months ago · wsj.com
Siemens Healthineers Cuts Revenue Outlook on Diagnostics WeaknessThe German supplier of medical equipment now expects fiscal-year revenue to grow by between 3.5% and 4.0% on a comparable basis, compared with 4.5% to 5% previously.
3 months ago · reuters.com
Siemens Healthineers cuts revenue forecast citing diagnostics weaknessMedical technology firm Siemens Healthineers cut its 2026 revenue growth forecast on Friday to a range of 3.5% to 4.0%, as China's procurement policy weighs on its diagnostics business.
Add to Watchlist
Select watchlists to add or remove SEMHF